Gatchalian SR - Search Results

1

Influenza in the Asia-Pacific region: Findings and recommendations from the Global Influenza Initiative.

Cowling BJ, Caini S, Chotpitayasunondh T, Djauzi S, Gatchalian SR, Huang QS, Koul PA, Lee PI, Muttalif AR, Plotkin S; Global Influenza Initiative. Cowling BJ, et al. Among authors: gatchalian sr. Vaccine. 2017 Feb 7;35(6):856-864. doi: 10.1016/j.vaccine.2016.12.064. Epub 2017 Jan 9. Vaccine. 2017. PMID: 28081970 Review.

2

Comparison of the immunogenicity and safety of measles vaccine administered alone or with live, attenuated Japanese encephalitis SA 14-14-2 vaccine in Philippine infants.

Gatchalian S, Yao Y, Zhou B, Zhang L, Yoksan S, Kelly K, Neuzil KM, Yaïch M, Jacobson J. Gatchalian S, et al. Vaccine. 2008 Apr 24;26(18):2234-41. doi: 10.1016/j.vaccine.2008.02.042. Epub 2008 Mar 18. Vaccine. 2008. PMID: 18394765 Clinical Trial.

3

Immunogenicity and safety of an adjuvanted inactivated polio vaccine, IPV-Al, compared to standard IPV: A phase 3 observer-blinded, randomised, controlled trial in infants vaccinated at 6, 10, 14 weeks and 9 months of age.

Bravo LC, Carlos JC, Gatchalian SR, Montellano MEB, Tabora CFCB, Thierry-Carstensen B, Tingskov PN, Sørensen C, Wachmann H, Bandyopadhyay AS, Nielsen PI, Kusk MV. Bravo LC, et al. Among authors: gatchalian sr. Vaccine. 2020 Jan 16;38(3):530-538. doi: 10.1016/j.vaccine.2019.10.064. Epub 2019 Nov 5. Vaccine. 2020. PMID: 31703934 Free PMC article. Clinical Trial.

4

Immunogenicity, reactogenicity and safety of the human rotavirus vaccine RIX4414 (Rotarix™) oral suspension (liquid formulation) when co-administered with expanded program on immunization (EPI) vaccines in Vietnam and the Philippines in 2006-2007.

Anh DD, Carlos CC, Thiem DV, Hutagalung Y, Gatchalian S, Bock HL, Smolenov I, Suryakiran PV, Han HH. Anh DD, et al. Vaccine. 2011 Mar 3;29(11):2029-36. doi: 10.1016/j.vaccine.2011.01.018. Epub 2011 Jan 21. Vaccine. 2011. PMID: 21256876 Clinical Trial.

5

Immunogenicity and safety of a varicella vaccine, Okavax, and a trivalent measles, mumps and rubella vaccine, MMR-II, administered concomitantly in healthy Filipino children aged 12-24 months.

Gatchalian S, Leboulleux D, Desauziers E, Bermal N, Borja-Tabora C. Gatchalian S, et al. Southeast Asian J Trop Med Public Health. 2003 Sep;34(3):589-97. Southeast Asian J Trop Med Public Health. 2003. PMID: 15115135 Clinical Trial.

6

A randomized comparative trial in order to assess the reactogenicity and immunogenicity of a new measles mumps rubella (MMR) vaccine when given as a first dose at 12-24 months of age.

Gatchalian S, Cordero-Yap L, Lu-Fong M, Soriano R, Ludan A, Chitour K, Bock HL. Gatchalian S, et al. Southeast Asian J Trop Med Public Health. 1999 Sep;30(3):511-7. Southeast Asian J Trop Med Public Health. 1999. PMID: 10774661 Clinical Trial.

7

Reactogenicity and immunogenicity of a live-attenuated refrigerator-stable varicella vaccine (OKA strain) in healthy seronegative subjects age 10 months to 12 years.

Hadinegoro SR, Hindra IS, Han HH, Gatchalian S, Bock HL. Hadinegoro SR, et al. Among authors: gatchalian s. Southeast Asian J Trop Med Public Health. 2009 Sep;40(5):991-9. Southeast Asian J Trop Med Public Health. 2009. PMID: 19842382

8

Immunogenicity of the Inactivated Japanese Encephalitis Virus Vaccine IXIARO in Children From a Japanese Encephalitis Virus-endemic Region.

Dubischar KL, Kadlecek V, Sablan JB, Borja-Tabora CF, Gatchalian S, Eder-Lingelbach S, Kiermayr S, Spruth M, Westritschnig K. Dubischar KL, et al. Pediatr Infect Dis J. 2017 Sep;36(9):898-904. doi: 10.1097/INF.0000000000001615. Pediatr Infect Dis J. 2017. PMID: 28430748 Clinical Trial.

9

Immunogenicity and safety of a varicella vaccine (Okavax) and a trivalent measles, mumps, and rubella vaccine (Trimovax) administered concomitantly in healthy Filipino children 12-24 months old.

Gatchalian S, Tabora C, Bermal N, Leboulleux D, Desauziers E. Gatchalian S, et al. Am J Trop Med Hyg. 2004 Mar;70(3):273-7. Am J Trop Med Hyg. 2004. PMID: 15031516 Clinical Trial.

10

Safety of the Inactivated Japanese Encephalitis Virus Vaccine IXIARO in Children: An Open-label, Randomized, Active-controlled, Phase 3 Study.

Dubischar KL, Kadlecek V, Sablan B Jr, Borja-Tabora CF, Gatchalian S, Eder-Lingelbach S, Mueller Z, Westritschnig K. Dubischar KL, et al. Pediatr Infect Dis J. 2017 Sep;36(9):889-897. doi: 10.1097/INF.0000000000001623. Pediatr Infect Dis J. 2017. PMID: 28441266 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

38 results

Search Page